Clementia Pharmaceuticals (NASDAQ:CMTA) and Millendo Therapeutics (NASDAQ:MLND) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, risk, valuation and institutional ownership.
This is a breakdown of recent recommendations for Clementia Pharmaceuticals and Millendo Therapeutics, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Risk and Volatility
Clementia Pharmaceuticals has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500. Comparatively, Millendo Therapeutics has a beta of 3.34, indicating that its share price is 234% more volatile than the S&P 500.
This table compares Clementia Pharmaceuticals and Millendo Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider and Institutional Ownership
78.7% of Clementia Pharmaceuticals shares are held by institutional investors. Comparatively, 43.8% of Millendo Therapeutics shares are held by institutional investors. 7.4% of Millendo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Valuation and Earnings
This table compares Clementia Pharmaceuticals and Millendo Therapeutics’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Clementia Pharmaceuticals||N/A||N/A||-$58.13 million||($7.93)||-3.34|
|Millendo Therapeutics||$290,000.00||737.10||-$27.19 million||($17.58)||-0.91|
Millendo Therapeutics has higher revenue and earnings than Clementia Pharmaceuticals. Clementia Pharmaceuticals is trading at a lower price-to-earnings ratio than Millendo Therapeutics, indicating that it is currently the more affordable of the two stocks.
Millendo Therapeutics beats Clementia Pharmaceuticals on 10 of the 13 factors compared between the two stocks.
Clementia Pharmaceuticals Company Profile
Clementia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops treatments for patients suffering from bone disorders and other diseases. Its lead product candidate is palovarotene, an oral small molecule for the treatment of fibrodysplasia ossificans progressive, multiple osteochondromas, dry eye disease, and other diseases is in the Phase 3 MOVE Trial. Clementia Pharmaceuticals Inc. was founded in 2010 and is based in Montreal, Canada.
Millendo Therapeutics Company Profile
Millendo Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of various treatments for orphan endocrine diseases in the United States. The company's lead drug candidates include livoletide, an unacylated ghrelin analogue to treat for Prader-Willi syndrome; and nevanimibe, which is in Phase 2b clinical development for the treatment of congenital adrenal hyperplasia and endogenous Cushing's syndrome. The company is based in Ann Arbor, Michigan.
Receive News & Ratings for Clementia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clementia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.